The Connecticut company’s long-lived logo is now getting a new look tailored for the future and the dramatic shift to digital ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

Slaughter and May has elected David Johnson as its next managing partner, succeeding Deborah Finkler in the role. The change ...

MicroStrategy Inc. (NASDAQ:MSTR) has officially rebranded as Strategy, reflecting its sharpened focus on Bitcoin ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.